Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting
November 15, 2015 at 09:55 AM EST
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of results ...
